Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541473 | 0.93 | CXCR4 (0.36) | CXCR4SCDMAPK8EPHX2JUN | |
| SCHEMBL541984 | 0.91 | CXCR4 (0.39) | CXCR4SCDVNN1JUNNFKB1 | |
| SCHEMBL542025 | 0.88 | LRRK2 (0.39) | CXCR4 | |
| SCHEMBL15397201 | 0.88 | CXCR4 (0.34) | CXCR4SCDMAPK8EPHX2 | |
| SCHEMBL6521503 | 0.88 | HDAC3 (0.41) | CXCR4SCDMAPK8EPHX2VNN1 | |
| SCHEMBL541599 | 0.86 | CXCR4 (0.36) | CXCR4SCDJUNNFKB1NFKB2 | |
| SCHEMBL541926 | 0.86 | CXCR4 (0.37) | CXCR4SCDMAPK8VNN1JUN | |
| SCHEMBL541918 | 0.85 | GSK3A (0.43) | CXCR4SCDMAPK8EPHX2 | |
| SCHEMBL542020 | 0.84 | CXCR4 (0.38) | CXCR4SCDVNN1JUNNFKB1 | |
| SCHEMBL541530 | 0.83 | CXCR4 (0.34) | CXCR4SCDMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CXCR4 350/4885SCD 1093/4885MAPK8 2238/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CXCR4 206/4885SCD 1251/4885MAPK8 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.